CSIMarket
 


Oxford Immunotec Global Plc  (OXFD)
Other Ticker:  
 

Oxford Immunotec Global Plc's Long Term Debt to Equity

OXFD's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In the third quarter 2020 Oxford Immunotec Global Plc did not have Long Term Debt.

Within In Vitro & In Vivo Diagnostic Substances industry Oxford Immunotec Global Plc achieved the lowest Long Term Debt to Equity in the third quarter 2020. While total ranking remained the same in the third quarter 2020 compared to the previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt OXFD´s has?
What is the structure of OXFD´s Equity?


OXFD Long Term Debt to Equity (Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
Y / Y Equity Change -11.03 % -13.27 % -8.41 % -0.15 % 198.71 %
Y / Y Long Term Debt Change - - 6.67 % -69.81 % -69.07 %
Long Term Debt to Equity MRQ - - 0 0 0
OXFD's Total Ranking # # # # #
Seq. Equity Change 1.25 % -4.6 % -7.34 % -0.59 % -1.29 %
Seq. Long Term Debt Change - - 0 % 6.67 % 0 %



Long Term Debt to Equity third quarter 2020 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Oxford Immunotec Global Plc's Equity $ 191 Millions Visit OXFD's Balance sheet
Oxford Immunotec Global Plc's Long Term Debt $ 0 Millions Visit OXFD's Balance sheet
Source of OXFD's Sales Visit OXFD's Sales by Geography


Cumulative Oxford Immunotec Global Plc's Long Term Debt to Equity

OXFD's Long Term Debt to Equity for the trailling 12 Months

OXFD Long Term Debt to Equity

(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
Y / Y Equity TTM Growth -11.03 % -13.27 % -8.41 % -0.15 % 198.71 %
Y / Y Long Term Debt TTM Growth - - 6.67 % -69.81 % -69.07 %
Long Term Debt to Equity TTM 0 0 0 0 0
Total Ranking TTM
Seq. Equity TTM Growth 1.25 % -4.6 % -7.34 % -0.59 % -1.29 %
Seq. Long Term Debt TTM Growth - - 0 % 6.67 % 0 %


On the trailing twelve months basis During the twelve months ending III Quarter 2020 Oxford Immunotec Global Plc did not have Long Term Debt .
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the In Vitro & In Vivo Diagnostic Substances industry OXFD recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 1.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt OXFD´s has?
What is the structure of OXFD´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 0
Healthcare Sector # 0
Within the Market #


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.41 0.11 0
(Dec 31 2017)   (Sep 30 2020)




Companies with similar Long Term Debt to Equity in the quarter ending Sep 30 2020, within In Vitro & In Vivo Diagnostic Substances Industry Long Term Debt to EquitySep 30 2020 MRQ Long Term DebtSep 30 2020 MRQ Equity

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com